摘要
心肌缺血/再灌注损伤是缺血心肌获得最佳疗效的主要障碍,目前临床中还无有效药物进行预防和治疗。三七是传统的化瘀止痛药物,临床中常用于治疗心绞痛、冠心病等,随着研究的深入,发现三七及其提取物能够调控多种信号通路,对心肌缺血/再灌注损伤产生保护作用,具有较广阔的应用前景。该文综述了近年来三七及其活性成分对心肌缺血/再灌注损伤的治疗作用及作用机制,以期为后期药物开发提供参考。
Myocardial ischemia/reperfusion injury ( MI/RI) is a pathophysiological phenomenon commonly seen during thromboly-sis, percutaneous transluminal coronary angioplasty ( PTCA ) , and coronary artery bypass grafting ( CABG ) . It is defined as restoration of blood flow to a previously ischemic region followed by complex pathological events leading to tissue injury greater than the original ischemic insult. Many experimental interven-tions have been reported to protect the ischemic myocardium in experimental animals; however, with the exception of early reperfusion, none has been translated into clinical practice. The root of Panax notoginseng ( Burk. ) F. H. Chen ( PN) is one of the iconic herbs in traditional Chinese medicine. Traditional pharmacopeia recommended it among the most efficacious herbs for‘promoting blood circulation ’ and hemostasis. Inspired by this, in the last decade, a large number of modern investigators made substantial efforts to search the PN activities against a vari-ety of MIRI. The systematic review was performed according to the protecting drug of the MIRI development guidelines.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2015年第10期1340-1344,共5页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 81503289
No 81303257)
中国博士后科学基金资助项目(No 2013M540067
2014T70054)